ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (CAS 846557-71-9) is a small molecule inhibitor of nuclear factor erythroid 2-related factor 2 (NRF2) with an IC₅₀ of 1.9 μM, used to dissect NRF2-dependent antioxidant and drug resistance pathways in cancer and liver injury models (Zhou et al., 2024; APExBIO). ML385 demonstrates dose- and time-dependent inhibition of NRF2-driven gene expression in A549 non-small cell lung cancer (NSCLC) cells (Related Article). In vivo, ML385 suppresses tumor growth and enhances chemotherapeutic efficacy, notably in combination with carboplatin. It is soluble at ≥13.33 mg/mL in DMSO, but insoluble in ethanol and water, requiring storage at −20°C for stability. ML385’s specificity enables robust investigation into NRF2-mediated oxidative stress, ferroptosis, and therapeutic resistance, with validated protocols for both cell and animal models (Related Article).

Biological Rationale

NRF2 is a transcription factor regulating cellular antioxidant responses, phase II detoxification enzymes, and multidrug resistance transporters. NRF2 activation counters oxidative stress by upregulating target genes including NAD(P)H dehydrogenase [quinone] 1 (NQO1), heme oxygenase-1 (HO-1), and glutathione S-transferases. In cancer, persistent NRF2 activation supports tumor survival, proliferation, and resistance to chemotherapy, particularly in NSCLC and hepatocellular carcinoma (Zhou et al., 2024). Aberrant NRF2 signaling is implicated in therapeutic resistance, metabolic reprogramming, and ferroptosis regulation. Targeting NRF2 with small molecule inhibitors like ML385 enables precise modulation of redox homeostasis and chemosensitization in preclinical studies. ML385, supplied by APExBIO, is widely adopted in studies investigating the role of NRF2 in oxidative stress–related diseases and cancer (product page).

Mechanism of Action of ML385

ML385 selectively binds to the Neh1 DNA-binding domain of NRF2, inhibiting its transcriptional activity. The compound disrupts NRF2’s ability to heterodimerize with small Maf proteins and bind to antioxidant response elements (ARE) in the promoters of target genes. This inhibition is dose-dependent, with an in vitro IC₅₀ of 1.9 μM. In A549 NSCLC cells, ML385 reduces expression of canonical NRF2 targets such as NQO1, HO-1, and GCLC in a time-dependent manner. The specificity of ML385 for NRF2 over other bZIP transcription factors has been verified using reporter assays and genetic controls (Related Article). ML385 does not act as a general cytotoxin, but rather modulates oxidative stress responses by impeding NRF2-driven gene expression, enabling mechanistic studies of redox regulation and drug resistance.

Evidence & Benchmarks

• ML385 inhibits NRF2 transcriptional activity in A549 NSCLC cells at an IC₅₀ of 1.9 μM. (APExBIO ML385)
• ML385 administration (100 mg/kg/day, i.p.) in mouse models reduces tumor growth and metastasis, especially when combined with carboplatin chemotherapy. (Zhou et al., 2024)
• In an alcoholic liver injury rat model, ML385 abrogates NRF2-mediated antioxidant gene induction, confirming on-target action in vivo. (Zhou et al., 2024)
• ML385 is insoluble in ethanol and water, but dissolves at ≥13.33 mg/mL in DMSO at room temperature (20–25°C). (APExBIO)
• ML385’s NRF2 inhibition is reversible; cessation of treatment restores downstream gene expression within 24–48 hours in cell models. (Related Article)

Applications, Limits & Misconceptions

ML385 is primarily used to dissect NRF2 signaling in cancer, oxidative stress, and ferroptosis models. Its selectivity allows for the study of NRF2-dependent transcriptional programs without broadly disrupting cellular homeostasis. In NSCLC models, ML385 resensitizes tumor cells to chemotherapeutics by downregulating multidrug transporter expression. In liver disease, ML385 clarifies the role of NRF2 in antioxidant defense and ferroptosis. However, interpretation of ML385 results requires careful control experiments, as NRF2-independent effects may arise at high concentrations or with prolonged exposure.

For further reading, 'ML385: Selective NRF2 Inhibitor for Cancer and Oxidative ...' offers a mechanistic primer, while this article provides updated benchmarks and in vivo data. 'ML385 (SKU B8300): Precision NRF2 Inhibition for Reliable...' details protocol optimization, which this article extends with new preclinical evidence and application parameters.

Common Pitfalls or Misconceptions

• ML385 is not a pan-antioxidant inhibitor: It specifically targets NRF2, not general ROS scavenging.
• Non-selective effects at high concentrations: Off-target cytotoxicity may occur above recommended doses (>10 μM in vitro).
• Solubility limits: ML385 is insoluble in water and ethanol; improper dissolution can result in precipitation and non-reproducible dosing.
• Reversible inhibition: Effects are transient; NRF2 activity returns after compound removal.
• Not suitable for chronic dosing in vivo without stability validation: Long-term solution storage decreases compound integrity.

Workflow Integration & Parameters

Preparation: Dissolve ML385 at ≥13.33 mg/mL in DMSO. Aliquot and store at −20°C. Avoid repeated freeze-thaw cycles and do not store solutions long-term. For cell-based assays, dilute ML385 in culture medium to a final concentration of 0.5–5 μM, ensuring DMSO does not exceed 0.1% v/v. For animal studies, dilute freshly in compatible vehicles and administer at 100 mg/kg/day, intraperitoneally, as validated in mouse models (Zhou et al., 2024).

Controls: Include DMSO-only controls and, where possible, NRF2 knockdown/knockout cell lines. Assess downstream gene expression (e.g., NQO1, HO-1) and phenotypic endpoints (cell viability, proliferation, ferroptosis markers).

Data Analysis: Monitor time- and dose-dependent effects on NRF2 targets. Document reversibility by washout experiments. Use parallel cytotoxicity assays to rule out off-target effects.

Conclusion & Outlook

ML385 (SKU B8300) provides a robust, selective tool for investigating NRF2 signaling, oxidative stress modulation, and mechanisms of cancer therapeutic resistance. Its well-characterized action and reproducible inhibition profile enable high-confidence interpretation of NRF2-dependent processes in cancer and liver disease models. As preclinical studies expand, ML385’s integration into combination therapy research and redox biology will continue to refine our understanding of therapeutic resistance and antioxidant response regulation. For official specifications, protocols, and ordering, see the APExBIO ML385 product page.